Phathom Pharmaceuticals is a leading biopharmaceutical company dedicated to revolutionizing the treatment options for individuals suffering from gastrointestinal (GI) diseases linked to acid. With a focus on acid-related disorders, Phathom Pharmaceuticals is committed to transforming the treatment landscape and enhancing the quality of life for patients. Their late clinical-stage programs offer innovative therapeutics for gastroesophageal reflux disease (GERD) in both erosive and non-erosive forms.

By going beyond traditional approaches, Phathom Pharmaceuticals aims to change the status quo and advance treatments for acid-related disorders. With in-depth expertise in developing and commercializing advanced therapeutics, Phathom Pharmaceuticals holds a strong commitment to scientific research and medical breakthroughs. They also provide access to the latest corporate information and investor resources, keeping shareholders up to date with upcoming events and press releases.

Discover the future of GI treatment with Phathom Pharmaceuticals – a brand dedicated to making a difference in the lives of patients and changing the landscape in GI healthcare